Nickel Desensitization Using Topical Therapy

• Status: Unknown status
• Trial end date: 2012-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Nickel contact dermatitis (eczema) is one of the most common allergic conditions affecting the skin. This is a study looking at potentially desensitizing nickel-allergic patients to their allergy using anti-inflammatory ointments applied to the skin (arm). Application of these ointments (ie. modified Vitamin D) has been shown to increase specific immune cells (T regulatory cells), which play a role in preventing immune activation and subsequently inflammation. The investigators propose use of topical anti-inflammatory agents (corticosteroids, modified Vitamin D, or both) may desensitize patients with nickel allergy.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of British Columbia
• Treatments: Betamethasone; Betamethasone benzoate; Betamethasone sodium phosphate; Betamethasone Valerate; Betamethasone-17,21-dipropionate; Calcipotriene; Calcitriol; Nickel

Criteria

Inclusion Criteria:

• Age > 18 years.

• Patients have had a diagnosis of nickel allergy determined by patch testing

Exclusion Criteria:

• Treatment with immunomodulating medications concurrently or in the previous one month

• Active skin disease, particularly to the site of application (forearms)

• Hypersensitivity to calcipotriol, corticosteroids, or vehicle

• Previous anaphylactic reactions to nickel allergen

• Pregnancy or breast-feeding